Abstract
BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Protein & Peptide Letters
Title:Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma
Volume: 20 Issue: 5
Author(s): Yongbing Li, Hanmei Xu, Jialiang Hu, Fengguo Zhang, Zhendong Liu, Chi Zhang, Yongjing Yang, Chunyan Pu, Linqiu Huang and Xin Wen
Affiliation:
Keywords: Integrin antagonist, AP25, indirect ELISA, pharmacokinetics, plasma protein binding rate, HPLC
Abstract: BALB/c mice were immunized by highly immunogenic recombinant proteins containing amino acid sequence of integrin antagonist AP25. Antibody against AP25 was prepared and purified by affinity chromatography. An indirect enzyme-linked immunosorbent assay for qualitative analysis of AP25 in rat plasma samples was successfully established. The assay was successfully applied to determine the pharmacokinetic parameters of AP25 in SD rats by intravenous administration of AP25 and then the rat plasma protein binding of AP25 were determined in vitro. In order to investigate the specificity of ELISA for detection of prototype AP25 in plasma, the proportion of AP25 prototype drug in the ELISA signal value was validated by HPLC. These results can serve as valuable future clinical trials.
Export Options
About this article
Cite this article as:
Li Yongbing, Xu Hanmei, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Huang Linqiu and Wen Xin, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein & Peptide Letters 2013; 20 (5) . https://dx.doi.org/10.2174/0929866511320050012
DOI https://dx.doi.org/10.2174/0929866511320050012 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Genetic Algorithm- Back Propagation Artificial Neural Network Model to Quantify the Affinity of Flavonoids Toward P-Glycoprotein
Combinatorial Chemistry & High Throughput Screening Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials
Current Pharmaceutical Design Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Effects of the Novel Non-Peptidyl Low Molecular Weight Radical Scavenger IAC in Different Models of Inflammation: A New Perspective in Anti-Inflammatory Therapy
Current Medicinal Chemistry Relation Between Helicobacter Pylori Infection and Gastroduodenal Diseases
Current Cancer Therapy Reviews Effects of Platinum Nanoparticles on Apoptosis
Recent Patents on Nanomedicine TWIST1 Gene: First Insights in Felis catus
Current Genomics Targeted Drug Delivery in Brain Tumors-nanochemistry Applications and Advances
Current Topics in Medicinal Chemistry Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Concentration-Dependent Bimodal Effect of Specific 18 kDa Translocator Protein (TSPO) Ligands on Cell Death Processes Induced by Ammonium Chloride: Potential Implications for Neuropathological Effects Due to Hyperammonemia
CNS & Neurological Disorders - Drug Targets Andrographolide Inhibits Osteopontin Expression and Breast Tumor Growth Through Down Regulation of PI3 Kinase/Akt Signaling Pathway
Current Molecular Medicine Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry A Review: The Anti-inflammatory, Anticancer and Antibacterial Properties of Four Kinds of Licorice Flavonoids Isolated from Licorice
Current Medicinal Chemistry Inhibitory Effects of Flavonolignans from Silybum marianum (L.) Gaertn (Milk Thistle) on Function of Aldehyde Oxidase and Xanthine Oxidase in Rats
Letters in Drug Design & Discovery Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Clavulanic Acid in the Scope of <i>Helicobacter pylori</i> Treatment: A Literature Review and Beyond
Current Reviews in Clinical and Experimental Pharmacology Development of Yeast Molecular Display Systems Focused on Therapeutic Proteins, Enzymes, and Foods: Functional Analysis of Proteins and its Application to Bioconversion
Recent Patents on Biotechnology Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets